Aberrant energy metabolism represents a hallmark of cancer and contributes to numerous aggressive behaviors of cancer cells, including cell death and survival. Despite the poor prognosis of mantle cell lymphoma (MCL), due to the inevitable development of drug resistance, metabolic reprograming of MCL cells remains an unexplored area. Posttranslational modification of proteins via O-GlcNAcylation is an ideal sensor for nutritional changes mediated by O-GlcNAc transferase (OGT) and is removed by O-GlcNAcase (OGA). Using various small-molecule inhibitors of OGT and OGA, we found for the first time that O-GlcNAcylation potentiates MCL response to bortezomib. CRISPR interference of MGEA5 (encoding OGA) validated the apoptosis sensitization by O-GlcNAcylation and OGA inhibition. To identify the potential clinical candidates, we tested MCL response to drug-like OGA inhibitor, ketoconazole, and verified that it exerts similar sensitizing effect on bortezomib-induced apoptosis. Investigations into the underlying molecular mechanisms reveal that bortezomib and ketoconazole act in concert to cause the accumulation of truncated Bid (tBid). Not only does ketoconazole potentiate tBid induction, but also increases tBid stability through O-GlcNAcylation that interferes with tBid ubiquitination and proteasomal degradation. Remarkably, ketoconazole strongly enhances bortezomib-induced apoptosis in de novo bortezomib-resistant MCL cells and in patient-derived primary cells with minimal cytotoxic effect on normal peripheral blood mononuclear cells and hepatocytes, suggesting its potential utility as a safe and effective adjuvant for MCL. Together, our findings provide novel evidence that combination of bortezomib and ketoconazole or other OGA inhibitors may present a promising strategy for the treatment of drug-resistant MCL. Mol Cancer Ther; 17(2); 484–96. ©2017 AACR.

Metabolic reprogramming is a hallmark of cancer that has emerged as an attractive target in novel therapeutic strategies for cancer treatment (1, 2). Mantle cell lymphoma (MCL), an aggressive non-Hodgkin lymphoma (NHL) arising from pregerminal center mature B cells, is typically incurable due to the inevitable development of drug resistance, and thus has the worst prognosis among NHL subtypes (3, 4). However, overcoming MCL resistance particularly through metabolic signaling remains largely an unexplored area.

O-GlcNAcylation is an abundant, dynamic, and nutrient-sensitive posttranslational modification (PTM) that describes an addition of O-linked β-N-acetylglucosamine (O-GlcNAc) moiety to the serine or threonine residues in proteins in response to changes of the sugar donor UDP-GlcNAc from hexosamine biosynthetic pathway (5, 6). As the hexosamine pathway consumes various essential nutrients and metabolic intermediates, for example, glucose and glutamine, acetyl coenzyme A, and nucleotide uridine-5′-triphosphate (UTP), it provides an ideal machinery for cells to sense and respond to a variety of microenvironmental conditions. Alterations in the levels of cycling enzymes O-GlcNAc transferase (OGT) and O-GlcNAcase (OGA) that catalyzes and removes O-GlcNAc, and the levels of O-GlcNAcylated proteins themselves, have been linked to many different human malignancies, including breast, lung, colon, prostate, bladder, and leukemia (7–11). In chronic lymphocytic leukemia (CLL), a recent study has shown that indolescent and aggressive clinical behaviors of CLL cells correlate well with the higher and lower levels of O-GlcNAc respectively, suggesting the potential involvement of O-GlcNAcylation in CLL pathogenesis (11).

Bortezomib has demonstrated impressive clinical efficacy and is FDA-approved for the treatment of relapse/refractory MCL. However, innate and acquired clinical resistance to bortezomib is frequently observed (12, 13). Because many nucleocytoplasmic proteins involved in the proliferation and survival of tumor cells are dramatically modified by O-GlcNAcylation, including p53, NFκB, and c-Myc (7, 14, 15), targeting O-GlcNAcylation might represent a rational approach to modulate MCL drug response. In this study, we used small-molecule inhibitors of OGT and OGA cycling enzymes to modify intracellular O-GlcNAcylation and to investigate its effect on bortezomib-induced apoptosis. We found that well known OGA inhibitors, including PugNAc and thiamet G (16, 17), sensitize MCL cells to bortezomib-induced apoptosis, while OGT inhibitor alloxan (18, 19) inhibits it. In an attempt to identify potential drug candidates for clinical utility, we further tested the effect of a drug-like OGA inhibitor, ketoconazole (20), on MCL response. Here, we showed that a conventional antifungal drug ketoconazole enhances the susceptibility of multiple parental and de novo bortezomib-resistant MCL cells as well as patient-derived primary cells to bortezomib-induced apoptosis. We also unveil the underlying mechanism of sensitization that is OGA inhibitors induce O-GlcNAcylation of truncated Bid (tBid) and strengthen apoptosis signaling by abrogating tBid ubiquitin-mediated proteasomal degradation, thus stabilizing tBid and prolonging its action. Our findings also suggest the role of hexosamine metabolic pathway in MCL drug response, which could be important in predicting therapeutic response and in developing new treatment strategies for drug-resistant MCL to achieve long-term control of the disease.

Reagents

Bortezomib was obtained from Jannsen-Cilag. Small-molecule inhibitors of OGA PugNAc and thiamet G were obtained from Abcam and Tocris Bioscience, while ketoconazole was obtained from Crosschem Intercontinental Company (Lugano, Switzerland). A small-molecule inhibitor of OGT alloxan and a small-molecule inhibitor of tBid BI-6C9 (21) were obtained from Sigma-Aldrich. Antibodies for ubiquitin and O-GlcNAc were obtained from Abcam, while antibody for tBid was from Santa Cruz Biotechnology. All other antibodies and reagents including MG132 and cycloheximide were from Cell Signaling Technology.

Cell lines and patient-derived primary cells

Human MCL-derived Jeko-1 cells were obtained from ATCC, while Granta-519 and SP49 cells were kind gifts of Dr. Siwanon Jirawatnotai (Systems Pharmacology, Faculty of Medicine Siriraj Hospital, Bangkok, Thailand; refs. 22, 23). Mycoplasma contamination was checked every eight weeks using MycoAlert mycoplasma detection kit (Lonza) and any cell lines found positive were discarded. Cells were cultured in RPMI1640 medium containing 10% FBS, supplemented with 2 mmol/L l-glutamine, 100 U/mL penicillin, and 100 μg/mL streptomycin, and maintained in a humidified atmosphere of 5% CO2 environment at 37° C. Patient-derived primary cells were from fresh biopsy-derived lymphoma tissues (lymph nodes) after informed consent and after approval by the Siriraj Institutional Review Board (#733/2557 EC1). Tissues were diced and forced through a fine metal sieve into RPMI culture medium. Mononuclear cells were then isolated by Ficoll–Hypaque gradient centrifugation and cultured in RPMI medium containing 20% FBS and 10% conditioned medium from MCL Granta-519 cells, as described previously (24). Peripheral blood mononuclear cells (PBMC) from healthy donors were used as normal control cells.

Apoptosis assays

Apoptosis was determined by Hoechst 33342 and Annexin V/propidium iodide (PI) assays. In the Hoechst assay, cells were incubated with 10 μg/mL Hoechst 33342 (Molecular Probes) for 30 minutes and analyzed for apoptosis by scoring the percentage of cells having condensed chromatin and/or fragmented nuclei by fluorescence microscopy (Eclipse Ti-U with NiS-Elements, Nikon). The apoptotic index was calculated as the percentage of cells with apoptotic nuclei over total number of cells. For Annexin V/PI assay, cells were harvested, washed and stained with Annexin V-FITC in binding buffer supplemented with 5 mmol/L calcium chloride for 15 minutes at room temperature and costained with PI (5 μg/mL). Samples were immediately analyzed by BD LSRFortessa flow cytometer (BD Biosciences) using a 488-nm excitation beam and 530-nm and 670-nm band-pass filter with CellQuest software.

Combination index analysis

Combination index (CI) was analyzed by the fixed-ratio model using CompuSyn software (ComboSyn Inc.), which is a computerized analytical simulation using the median-effect principle of the mass-action law and its combination index theorem (25). Cells were treated with 12 concentrations of bortezomib each in combination with 12 concentrations of ketoconazole at the ratio of 1 to 10,000 or 1 to 5,000, and Fa (fraction affected) on cell apoptosis was determined by Hoechst 33342 assay. Each drug was also used alone and each data point was performed in triplicates.

CRISPR interference design and vector construction

CRISPR interference system containing catalytically inactive version of Cas9 (deactivated Cas9; dCas9) and a single guided RNA (sgRNA) was used to induce transcriptional repression of MGEA5 (encoded OGA). Briefly, sgRNA targeting MGEA5 (CGCAAGCGCAGTGCGGATAAAC) was designed using CRISPR Design tool (http://crispr.mit.edu/) and cloned into human sgRNA expression vector containing a mouse U6 promoter and a constitutive CMV promoter driving an mCherry gene (Addgene, #44248; ref. 26), as described previously (27). The constructed sgRNA plasmid was then transfected into Jeko-1 cells stably expressing human dCas9 vector (Addgene, #44246; ref. 26) by nucleofection using 4D-Nucleofector (Lonza) with EW113 device program. Two weeks after nucleofection, mCherry-positive cells were sorted using flow cytometry–based cell sorter (FACS; BD FACSAria, BD Biosciences), recovered for at least three passages, and analyzed for MGEA5 by RT-PCR and OGA by Western blotting prior to use.

RNA isolation and RT-PCR

Total RNA was prepared using TRIzol reagent (Invitrogen). cDNA was prepared using SuperScript III first-strand synthesis system and oligo (dT) primers (Invitrogen). qPCR analysis was carried out on a 7500 Fast real-time PCR using a Power SYBR Green PCR master mix (Applied Biosystems). Initial enzyme activation was performed at 95°C for 10 minutes, followed by 40 cycles of denaturation at 95°C for 15 seconds and primer annealing/extension at 60°C for 1 minute. Relative expression of each gene was normalized against the housekeeping GAPDH gene product.

PPISURV analysis

PPISURV was used to correlate survival rates in cancer patients to the expression level of MGEA5. Samples were separated into low and high expression groups with respect to expression rank of the gene, which reflects relative mRNA expression level, based on the average expression across the dataset. The R statistical package was used to perform survival analyses and to draw Kaplan–Meier plots. Unadjusted P values were generated using standard survival analysis package (28).

Caspase-8 activity assay

Caspase-8 activity was determined by detecting the cleavage of specific substrate IETD-AFC using a commercial assay kit (Biovision). After treatments, cell lysates were prepared and incubated with IETD-AFC (50 μmol/L) for 1 hour. Free AFC fluorescence was measured using a fluorescence plate reader (Synergy H1, BioTek) at the 400-nm and 505-nm excitation and emission wavelengths. Caspase-8 activity was expressed as the ratio of signals from the treated and control samples.

Western blot analysis

After specific treatments, cells were incubated in a commercial lysis buffer (Cell Signaling Technology) and a protease inhibitor mixture (Roche Molecular Biochemicals) at 4°C for 30 minutes. Protein content was analyzed using BCA protein assay (Pierce Biotechnology) and 50–150 μg of proteins were resolved under denaturing conditions by SDS-PAGE as described previously (29).

Retrovirus production and short hairpin RNA–mediated gene knockdown

Retroviral plasmids carrying short hairpin (sh) RNA sequence against human BID were obtained from Origene and shBID retroviral production was performed using Platinum-A packaging cells (Cell Biolabs, Inc). Cells were incubated with shBID viral particles in the presence of hexadimethrine bromide (8 μg/mL) for 48 hours and were cultured and selected for puromycin (1 μg/mL) resistance.

Overexpression plasmid and transfection

Cells were transfected with tBID (Addgene, #21149; ref. 30) or GFP (Invitrogen) plasmid by nucleofection using 4D-Nucleofector (Lonza) with EW113 device program. The transfected cells were cultured with G418-containing medium (400 μg/mL) and stable transfectants (clone #1 and #2) were selected and identified by Western blotting.

Coimmunoprecipitation, ubiquitination, and O-GlcNAcylation

Cell lysates (200 μg protein) were immunoprecipitated using Dynabeads magnetic beads (Invitrogen). Briefly, the beads were conjugated with anti-tBid (h71) antibody for 10 minutes at room temperature. The conjugated beads were then resuspended with cell lysates for 30 minutes at room temperature. The immune complexes were washed four times and resuspended in 2× Laemmli sample buffer. They were then separated by SDS-PAGE and analyzed for ubiquitination or O-GlcNAcylation using anti-ubiquitin or anti-O-GlcNAc (RL2) antibody, respectively.

Cycloheximide-chase assay

Cells were treated with cycloheximide (10 μg/mL) to inhibit new protein synthesis for various times (0–16 hours) to follow the degradation of protein by Western blot analysis (29). tBid expression profile was plotted and tBid half-life was calculated using GraphPad Prism software.

Generation of de novo bortezomib-resistant cells

Bortezomib-resistant cell lines were generated by stepwise selection method as described previously with slight modifications (31). Parental MCL-derived Jeko-1 (Jeko/Parent) and Granta-519 (Granta/Parent) cells were continuously exposed to increasing concentrations of bortezomib to the maximum concentration of 500 nmol/L in Jeko/Parent cells and 150 nmol/L in Granta/Parent cells, and resistant cells were selected using Dead Cell Removal Kit (Miltenyi Biotec) and designated as Jeko/BTZ500R and Granta/BTZ150R.

Statistical analysis

The data represent means ± SD from three or more independent experiments as indicated. Statistical analysis was performed by Student t test at a significance level of P < 0.05. An ANOVA followed by Mann–Whitney U test was used for a multiple pairwise comparison.

O-GlcNAcase inhibitors increase bortezomib sensitivity in MCL cells

To investigate the potential role of O-GlcNAcylation in bortezomib sensitivity, we modulated intracellular O-GlcNAcylation level using various known small-molecule inhibitors of specific enzymes in the hexosamine pathway, as schematically depicted in Fig. 1A (left). First, we determined the subtoxic concentrations of these inhibitors in the tested cell systems to ensure that the observed effects are not due to the cytotoxicity of the inhibitors. MCL Jeko-1, Granta-519, and SP49 cells were treated with well-known inhibitors of OGA (PugNAc and thiamet G), drug-like OGA inhibitor (ketoconazole), and OGT inhibitor (alloxan), and their effect on cell apoptosis was determined by Hoechst 33342 assay. We identified the appropriate noncytotoxic concentrations of these inhibitors, that is, up to 50 μmol/L for PugNAc, 15 μmol/L for thiamet G, 1.5 mmol/L for alloxan, and 75 μmol/L for ketoconazole (Fig. 1A, right; see also Supplementary Figs. S1 and S2). To evaluate their effect on bortezomib sensitivity, cells were pretreated with the inhibitors for 1 hour, followed by bortezomib treatment and apoptosis was determined after 24 hours. Figure 1B and Supplementary Table S1 show that the OGA inhibitors PugNAc and thiamet G significantly enhanced the sensitivity of MCL cells to bortezomib (5–7 nmol/L). In contrast, the OGT inhibitor alloxan abrogated bortezomib-induced apoptosis, suggesting the role of O-GlcNAcylation in MCL apoptotic response.

Figure 1.

O-GlcNAcase inhibitors increase the sensitivity of MCL cells to bortezomib (BTZ). A, (left) Schematic diagram for the O-GlcNAcylation, showing cycling enzymes OGT and OGA, and small-molecule inhibitors that modulate OGA, including PugNAc, thiamet G and ketoconazole (KCZ), and that modulate OGT, including alloxan. (right) Effect of OGT and OGA inhibitors on cell apoptosis to ensure their subcytotoxic concentrations. Data are mean ± SD (n = 3). NS, not significance versus nontreated cells; NTX, nontreatment. B, Effect of small-molecule OGA or OGT inhibitors on bortezomib-induced MCL cell apoptosis. Cells were treated with bortezomib (0–7 nmol/L) in the presence or absence of PugNAc (25–75 μmol/L), thiamet G (5–15 μmol/L), alloxan (0.5–1.5 mmol/L), or ketoconazole (25–75 μmol/L) and apoptosis was determined after 24 hours by Hoechst 33342 assay. Mean percentage of apoptosis from four independent experiments in Jeko-1, Grant-519, and SP49 cells are shown in the drug dose matrix data in 3-color scale, where green, black, and red indicate lowest, midpoint, and highest apoptosis, respectively (see also Supplementary Table S1 for raw data and statistical analysis). C, Percentage of apoptosis in response to bortezomib and drug-like OGA or OGT inhibitor cotreatment is plotted. Data are mean ± SD (n = 4). *, P < 0.05 versus bortezomib-treated cells; two-sided Student t test.

Figure 1.

O-GlcNAcase inhibitors increase the sensitivity of MCL cells to bortezomib (BTZ). A, (left) Schematic diagram for the O-GlcNAcylation, showing cycling enzymes OGT and OGA, and small-molecule inhibitors that modulate OGA, including PugNAc, thiamet G and ketoconazole (KCZ), and that modulate OGT, including alloxan. (right) Effect of OGT and OGA inhibitors on cell apoptosis to ensure their subcytotoxic concentrations. Data are mean ± SD (n = 3). NS, not significance versus nontreated cells; NTX, nontreatment. B, Effect of small-molecule OGA or OGT inhibitors on bortezomib-induced MCL cell apoptosis. Cells were treated with bortezomib (0–7 nmol/L) in the presence or absence of PugNAc (25–75 μmol/L), thiamet G (5–15 μmol/L), alloxan (0.5–1.5 mmol/L), or ketoconazole (25–75 μmol/L) and apoptosis was determined after 24 hours by Hoechst 33342 assay. Mean percentage of apoptosis from four independent experiments in Jeko-1, Grant-519, and SP49 cells are shown in the drug dose matrix data in 3-color scale, where green, black, and red indicate lowest, midpoint, and highest apoptosis, respectively (see also Supplementary Table S1 for raw data and statistical analysis). C, Percentage of apoptosis in response to bortezomib and drug-like OGA or OGT inhibitor cotreatment is plotted. Data are mean ± SD (n = 4). *, P < 0.05 versus bortezomib-treated cells; two-sided Student t test.

Close modal

We also investigated the effect of drug-like OGA inhibitor ketoconazole on bortezomib sensitivity due to its potential clinical application. Similar to the well-known small-molecule OGA inhibitors, ketoconazole (25–75 μmol/L) dose dependently promoted the apoptotic effect of bortezomib in all MCL cell lines tested (Fig. 1C; Supplementary Table S1). Flow cytometric analysis using Annexin V-FITC and PI double staining further confirmed the observed sensitizing effect of ketoconazole on bortezomib apoptosis, as indicated by an increase in the proportion of Annexin V–positive cells (Fig. 2A). To strengthen that the combination of bortezomib and ketoconazole would have added benefits, CI values were calculated based on the fixed-ratio model using CompuSyn software to define whether the two drugs are synergistic (CI < 1), additive (CI = 1), or antagonistic (CI > 1). Strong synergy was observed along the magnitude of apoptosis in all cell tested (Fig. 2B), indicating the potential application of ketoconazole.

Figure 2.

Drug-like OGA inhibitor ketoconazole (KCZ) sensitizes MCL cells to bortezomib (BTZ)-induced apoptosis. A, MCL cells were treated with bortezomib (6 nmol/L) in the presence of increasing concentrations of ketoconazole (0–75 μmol/L) for 24 hours and analyzed for apoptosis and necrosis by flow cytometry using Annexin V and propidium iodide (PI) as probes. Representative dot plots of Annexin V (x-axis) and PI (y-axis) are shown. Early and late apoptotic cells are in the lower and upper right quadrants with Annexin V positive. NTX, nontreatment. B, Combination index (CI) analysis by the fixed-ratio model. MCL cells were treated with bortezomib and ketoconazole at the ratio of 1 to 10,000 and 1 to 5,000 and CI values were calculated and predicted (trendlines) using CompuSyn software. CI  =  1, additivity; CI > 1, antagonism; CI < 1, synergy. C, Transcriptional repression of MGEA5 (encoding OGA) was performed using CRISPR interference. (left) Quantitative real-time PCR of MGEA5 mRNA expression and Western blot analysis of OGA protein level in control (dCas9) and OGA-knockdown (dCas9/MGEA5) Jeko-1 and Granta-519 cells. (right) Effect of OGA inhibition on bortezomib-induced apoptosis. Cells were treated with bortezomib (0–7 nmol/L) for 24 hours and apoptosis was determined by Hoechst 33342 assay. Data are mean ± SD (n = 3). *, P < 0.05 versus bortezomib-treated dCas9 control cells; two-sided Student t test. D, Kaplan–Meier survival curve of patients with DLBCL, segregated according to high (red) or low (green) expression of MGEA5 (encoding OGA), obtained from public database through a bioinformatics analysis using PPISURV (www.bioprofiling.de).

Figure 2.

Drug-like OGA inhibitor ketoconazole (KCZ) sensitizes MCL cells to bortezomib (BTZ)-induced apoptosis. A, MCL cells were treated with bortezomib (6 nmol/L) in the presence of increasing concentrations of ketoconazole (0–75 μmol/L) for 24 hours and analyzed for apoptosis and necrosis by flow cytometry using Annexin V and propidium iodide (PI) as probes. Representative dot plots of Annexin V (x-axis) and PI (y-axis) are shown. Early and late apoptotic cells are in the lower and upper right quadrants with Annexin V positive. NTX, nontreatment. B, Combination index (CI) analysis by the fixed-ratio model. MCL cells were treated with bortezomib and ketoconazole at the ratio of 1 to 10,000 and 1 to 5,000 and CI values were calculated and predicted (trendlines) using CompuSyn software. CI  =  1, additivity; CI > 1, antagonism; CI < 1, synergy. C, Transcriptional repression of MGEA5 (encoding OGA) was performed using CRISPR interference. (left) Quantitative real-time PCR of MGEA5 mRNA expression and Western blot analysis of OGA protein level in control (dCas9) and OGA-knockdown (dCas9/MGEA5) Jeko-1 and Granta-519 cells. (right) Effect of OGA inhibition on bortezomib-induced apoptosis. Cells were treated with bortezomib (0–7 nmol/L) for 24 hours and apoptosis was determined by Hoechst 33342 assay. Data are mean ± SD (n = 3). *, P < 0.05 versus bortezomib-treated dCas9 control cells; two-sided Student t test. D, Kaplan–Meier survival curve of patients with DLBCL, segregated according to high (red) or low (green) expression of MGEA5 (encoding OGA), obtained from public database through a bioinformatics analysis using PPISURV (www.bioprofiling.de).

Close modal

Next, CRISPR interference (CRISPR/dCas9) targeting MGEA5 (encoding OGA) was used to repress MGEA5 expression. The OGA-knockdown (dCas9/MGEA5) cells were established and their apoptotic response to bortezomib was examined in comparison with control (dCas9) cells. Figure 2C shows that bortezomib induced more apoptosis in the knockdown cells than control cells, thus confirming the apoptosis sensitization by O-GlcNAcylation and OGA inhibition. Using PPISUV bioinformatics tool, we analyzed the association between MGEA5 (encoding OGA) expression and clinical outcomes of patients with NHL, diffuse large B-cell lymphoma (DLBCL) subtype (due to the availability of data) and found that high expression of MGEA5 correlates well with low survival rates of patients (Fig. 2D). These clinical data support the involvement of O-GlcNAcylation in controlling of aggressive lymphoma.

Cleavage of Bid contributes to ketoconazole-mediated sensitization to bortezomib

To characterize the apoptotic response to bortezomib and ketoconazole, MCL Jeko-1, Granta-519 and SP49 cells were treated with bortezomib (0–6 nmol/L) alone or in combination with ketoconazole (75 μmol/L) in the presence or absence of caspase inhibitor z-DEVD-fmk (10–15 μmol/L). z-DEVD-fmk significantly but not completely suppressed bortezomib-induced apoptosis, suggesting that bortezomib induces both caspase-dependent and -independent apoptotic process. On the other hand, the inhibition of apoptosis by z-DEVD-fmk was more prominent in bortezomib and ketoconazole cotreatment, indicating that apoptosis sensitization by ketoconazole is associated with caspase activation (Supplementary Fig. S3A and S3B). Western blot analysis shows a dose-dependent increase in caspase-3 activation and PARP cleavage by bortezomib, which was further increased by the addition of ketoconazole, in concomitant with the observed changes in caspase-3 activity (Supplementary Fig. S3C). Caspase-9 serves as the apical caspase of the intrinsic apoptosis pathway, while caspase-8 represents the apical caspase of the extrinsic pathway (32, 33). Caspase-8 inhibitor (z-LEHD-fmk) and to a lesser extent caspase-9 inhibitor (z-IETD-fmk) significantly inhibited caspase-3 activation induced by the cotreatment, suggesting that the sensitizing effect of ketoconazole involves both intrinsic and extrinsic pathways.

To elucidate the underlying mechanisms of ketoconazole -mediated sensitization, we monitored the expression levels of various apoptosis-regulatory proteins, including Bcl-2, Bax, Bid, Mcl-1, p53, p73, and Cav-1 following the ketoconazole and bortezomib treatment. The results show that Bcl-2/Bax ratio was relatively unchanged, while p53 and p73 were undetectable, and Cav-1 level was fluctuated after the treatment with bortezomib alone or with ketoconazole (Fig. 3A), suggesting their nondominant role in the apoptotic process. While bortezomib alone caused a marked increase in the apoptotic fragments of Mcl-1, addition of ketoconazole did not potentiate this effect, suggesting its unlikely involvement in the ketoconazole sensitization process. Remarkably, we observed a downregulation of Bid and a striking upregulation of transcated Bid (tBid; Bid cleavage) in the bortezomib and ketoconazole cotreated cells along with an increase in caspase-9 activation. These results suggest the potential involvement of tBid in the sensitization process.

Figure 3.

Drug-like OGA inhibitor ketoconazole (KCZ) cleaves Bid to its truncated active form tBid. A, Analysis of apoptosis-signaling proteins in response to bortezomib (BTZ) and ketoconazole cotreatment. MCL Jeko-1 cells were treated with various concentrations of bortezomib (0–7 nmol/L) and ketoconazole (25–75 μmol/L) for 24 hours and analyzed for key apoptosis-regulatory proteins, including Bcl-2, Bax, p53, p73, Mcl-1, caveolin-1 (Cav-1), Bid, and caspase-9 (C9) using Western blotting. Blots were reprobed with anti-β-actin antibody to confirm equal loading of the samples. B, Ketoconazole potentiates caspase-8 activation and Bid cleavage in bortezomib-treated cells. Cells were treated with various concentrations of bortezomib and ketoconazole for 24 hours and the levels of pro- and activated caspase-8 (C8) as well as Bid and tBid were determined by Western blotting. Quantitative analysis of Bid and tBid by densitometry is shown. Data are mean ± SD (n = 4). *, P < 0.05 versus nontreated cells; two-sided Student t test. #, P < 0.05 versus bortezomib-treated cells; two-sided Student's t test. C, C8 activity was evaluated in the cells treated with bortezomib (6 nmol/L) and increasing concentrations of ketoconazole (0–75 μmol/L) for 16 hours using the fluorometric substrate IETD-AFC. Data are mean ± SD (n = 3). Data are mean ± SD (n = 3). *, P < 0.05 versus nontreated cells; two-sided Student t test. #, P < 0.05 versus bortezomib-treated cells; two-sided Student t test.

Figure 3.

Drug-like OGA inhibitor ketoconazole (KCZ) cleaves Bid to its truncated active form tBid. A, Analysis of apoptosis-signaling proteins in response to bortezomib (BTZ) and ketoconazole cotreatment. MCL Jeko-1 cells were treated with various concentrations of bortezomib (0–7 nmol/L) and ketoconazole (25–75 μmol/L) for 24 hours and analyzed for key apoptosis-regulatory proteins, including Bcl-2, Bax, p53, p73, Mcl-1, caveolin-1 (Cav-1), Bid, and caspase-9 (C9) using Western blotting. Blots were reprobed with anti-β-actin antibody to confirm equal loading of the samples. B, Ketoconazole potentiates caspase-8 activation and Bid cleavage in bortezomib-treated cells. Cells were treated with various concentrations of bortezomib and ketoconazole for 24 hours and the levels of pro- and activated caspase-8 (C8) as well as Bid and tBid were determined by Western blotting. Quantitative analysis of Bid and tBid by densitometry is shown. Data are mean ± SD (n = 4). *, P < 0.05 versus nontreated cells; two-sided Student t test. #, P < 0.05 versus bortezomib-treated cells; two-sided Student's t test. C, C8 activity was evaluated in the cells treated with bortezomib (6 nmol/L) and increasing concentrations of ketoconazole (0–75 μmol/L) for 16 hours using the fluorometric substrate IETD-AFC. Data are mean ± SD (n = 3). Data are mean ± SD (n = 3). *, P < 0.05 versus nontreated cells; two-sided Student t test. #, P < 0.05 versus bortezomib-treated cells; two-sided Student t test.

Close modal

Because tBid links the extrinsic to intrinsic apoptosis pathway (34, 35), we evaluated and found an increase in caspase-8 activation in parallel with tBid induction in all MCL cell lines tested following their treatment with bortezomib and ketoconazole (Fig. 3B). We confirmed by qPCR analysis that BCL2, BAX, TP53, MCL1, CAV1, and BID showed no appreciable changes in their expression in a way that would promote apoptosis (Supplementary Fig. S4), except for TP53 in response to ketoconazole at 75 μmol/L. We postulate that although p53 was not a likely target of O-GlcNAcylation in the current setting, due to its undetectable protein level, ketoconazole at higher doses might induce apoptosis in part through an upregulation of TP53. To validate the role of tBid in the ketoconazole-sensitizing effect, tBid was inhibited directly and indirectly by small-molecule inhibitor of tBid (BI-6C9) and RNA interference using shRNA against BID. Consistent with a recent report on the antiapoptotic function of full-length Bid in mouse embryonic fibroblasts (36), we observed that knockdown of Bid slightly promoted bortezomib-induced apoptosis, but abolished the sensitizing effect of ketoconazole (Fig. 4A, middle), suggesting the role of Bid/tBid in the sensitizing process. Specific inhibition of tBid by BI-6C9 effectively reversed the ketoconazole-sensitizing effect (Fig. 4A, bottom), indicating that tBid is a key mediator in this process. Notably, the inhibition of BI-6C9 on bortezomib-induced apoptosis was observed only at a high dose (20 μmol/L), suggesting that other regulators are likely to be involved in the apoptosis induced by bortezomib alone.

Figure 4.

tBid is a key mediator of ketoconazole (KCZ) sensitization of bortezomib (BTZ)-induced apoptosis. A, (upper) A schematic diagram for the inhibition of truncated Bid (tBid) using a small-molecule inhibitor of tBid (BI-6C9) and RNA interference of Bid (shBID) in MCL Jeko-1 and Granta-519 cells. Middle, inhibition of Bid by shBid diminishes the sensitizing effect of ketoconazole on bortezomib-induced apoptosis. shCON and shBID cells were similarly treated with bortezomib (0–7 nmol/L) in the presence or absence of ketoconazole (50–75 μmol/L) for 24 hours and apoptosis was determined by Hoechst 33342 assay. Data are mean ± SD (n = 3) *, P < 0.05 versus nontreated cells; two-sided Student t test. #, P < 0.05 versus bortezomib-treated cells; two-sided Student t test. Bottom, inhibition of tBid reverses the sensitizing effect of ketoconazole on bortezomib-induced apoptosis. Cells were cotreated with bortezomib (6 nmol/L) and ketoconazole (75 μmol/L) in the presence or absence of the tBid inhibitor BI-6C9 (10–20 μmol/L) and analyzed for apoptosis by Hoechst 33342 assay. Data are mean ± SD (n = 3). *, P < 0.05 versus nontreated cells; two-sided Student t test. #, P < 0.05 versus bortezomib-treated cells; two-sided Student t test. §, P < 0.05 versus bortezomib-treated cells in the presence of ketoconazole; two-sided Student t test. NTX, nontreatment. B, ketoconazole increases tBid stability in bortezomib-treated cells. Jeko-1 and Granta-519 cells were treated with bortezomib and ketoconazole in the presence or absence of the protein translation inhibitor cycloheximide (CHX; 10 μg/mL) for various times (0–16 hours) to follow the degradation of tBid protein. Cell lysates were prepared and tBid expression was determined by Western blotting. Representative immunoblots of tBid and loading control β-actin are shown. Expression–time profiles of tBid in Jeko-1 (solid lines) and Granta-519 (dashed lines) cells treated with CHX and bortezomib alone (circle) or with ketoconazole (square) were plotted and tBid half-lives were calculated and shown. Data are mean ± SD (n = 3). *, P < 0.05 versus bortezomib and CHX cotreated cells; two-sided Student t test.

Figure 4.

tBid is a key mediator of ketoconazole (KCZ) sensitization of bortezomib (BTZ)-induced apoptosis. A, (upper) A schematic diagram for the inhibition of truncated Bid (tBid) using a small-molecule inhibitor of tBid (BI-6C9) and RNA interference of Bid (shBID) in MCL Jeko-1 and Granta-519 cells. Middle, inhibition of Bid by shBid diminishes the sensitizing effect of ketoconazole on bortezomib-induced apoptosis. shCON and shBID cells were similarly treated with bortezomib (0–7 nmol/L) in the presence or absence of ketoconazole (50–75 μmol/L) for 24 hours and apoptosis was determined by Hoechst 33342 assay. Data are mean ± SD (n = 3) *, P < 0.05 versus nontreated cells; two-sided Student t test. #, P < 0.05 versus bortezomib-treated cells; two-sided Student t test. Bottom, inhibition of tBid reverses the sensitizing effect of ketoconazole on bortezomib-induced apoptosis. Cells were cotreated with bortezomib (6 nmol/L) and ketoconazole (75 μmol/L) in the presence or absence of the tBid inhibitor BI-6C9 (10–20 μmol/L) and analyzed for apoptosis by Hoechst 33342 assay. Data are mean ± SD (n = 3). *, P < 0.05 versus nontreated cells; two-sided Student t test. #, P < 0.05 versus bortezomib-treated cells; two-sided Student t test. §, P < 0.05 versus bortezomib-treated cells in the presence of ketoconazole; two-sided Student t test. NTX, nontreatment. B, ketoconazole increases tBid stability in bortezomib-treated cells. Jeko-1 and Granta-519 cells were treated with bortezomib and ketoconazole in the presence or absence of the protein translation inhibitor cycloheximide (CHX; 10 μg/mL) for various times (0–16 hours) to follow the degradation of tBid protein. Cell lysates were prepared and tBid expression was determined by Western blotting. Representative immunoblots of tBid and loading control β-actin are shown. Expression–time profiles of tBid in Jeko-1 (solid lines) and Granta-519 (dashed lines) cells treated with CHX and bortezomib alone (circle) or with ketoconazole (square) were plotted and tBid half-lives were calculated and shown. Data are mean ± SD (n = 3). *, P < 0.05 versus bortezomib and CHX cotreated cells; two-sided Student t test.

Close modal

tBid degradation is mediated by ubiquitin-mediated proteasomal degradation

The stability of tBid is an important factor in determining its apoptotic activity (37, 38). We tested whether tBid stability is controlled by proteasomal degradation in MCL cells. MCL Jeko-1 cells were treated with the proteasome inhibitor MG132 and tBid expression was determined by Western blotting using specific tBid antibody (h71). The result shows that the MG132 treatment increases the level of tBid, suggesting its regulation by proteasomal degradation (Supplementary Fig. S5A). Ubiquitination is a PTM process that triggers proteasomal degradation (39, 40). With a low basal level of tBid, cells were first induced to overexpress tBid by gene transfection, and its ubiquitination was examined by Western blotting. Supplementary Figure S5C shows that treatment of the cells with the proteasome inhibitor MG132 strongly induced polyubiquitination of tBid, supporting ubiquitin-mediated proteasomal degradation of the protein.

On the basis of the observed sensitizing effect of ketoconazole and the role of tBid in the process, we hypothesized that ketoconazole might cause tBid accumulation by regulating of tBid stability. To test this possibility, we evaluated the expression–time profile of tBid in MCL cells treated with bortezomib with or without ketoconazole. The results show that the combination treatment dramatically shortened tBid induction from 16 to 6 hours compared with bortezomib treatment alone (Supplementary Fig. S6). tBid protein half-life was further evaluated in both treatment groups by a cycloheximide-chase assay. In this assay, the tBid half-life following inhibition of new protein synthesis by cycloheximide was calculated, revealing a gradual decrease in tBid expression over time when the cells were treated with bortezomib alone (Fig. 4B). In contrast, the tBid expression continued to increase when the cells were treated with both bortezomib and ketoconazole even in the absence of new protein synthesis, indicating the stabilization of tBid following the combination treatment.

O-GlcNAcylation of tBid reduces its ubiquitination

PTMs like phosphorylation are known to influence protein stability through ubiquitin-mediated proteasomal degradation (41, 42). As O-GlcNAcylation occurs on serine and/or threonine residues of protein similarly to phosphorylation (5, 6), it is conceivable that ketoconazole might induce O-GlcNAcylation of tBid, which interferes with its ubiquitination. MCL Jeko-1, Granta-519, and SP49 cells were treated with bortezomib and ketoconazole, and tBid was immunoprecipitated and subjected to Western blot analysis using an O-GlcNAc–specific antibody (RL2). The level of tBid O-GlcNAcylation was found to increase markedly in the presence of ketoconazole in all tested cells (Fig. 5A). tBid ubiquitination was further analyzed after the bortezomib and ketoconazole cotreatment. Figure 5B shows that ketoconazole indeed reduced tBid ubiquitination, possibly through its induction of tBid O-GlcNAcylation. A similar result was observed when the cells were treated with another OGA inhibitor, PugNAc. Further analysis of the correlation between tBid O-GlcNAcylation and ubiquitination in the tested cells reveals the inverse relationship of the two events with a correlation coefficient (r) of −0.7760 (Fig. 5C), thus supporting the interfering effect of O-GlcNAcylation on tBid ubiquitination.

Figure 5.

Drug-like OGA inhibitor ketoconazole (KCZ) increases the O-GlcNAcylation but decreases the ubiquitination of tBid. A, Analysis of O-GlcNAcylation of tBid in response to bortezomib (BTZ) and ketoconazole cotreatment. MCL cells were cotreated with bortezomib (6 nmol/L) and increasing concentrations of KCZ (25–75 μmol/L) or PugNAc (50 μmol/L) for 3 hours. Cell lysates were prepared and immunoprecipitated using control IgG or anti-tBid (h71) antibody and probed with anti-O-GlcNAc antibody. Immunoblots were performed on cell lysates used as IP input using anti-β-actin antibody to confirm equal loading of the samples. B, Analysis of tBid ubiquitination in response to bortezomib and ketoconazole cotreatment. Cells were cotreated with bortezomib (6 nmol/L) and ketoconazole (25–75 μmol/L) or PugNAc (50 μmol/L) in the presence of MG132 (50 μmol/L) for 3 hours. Cell lysates were immunoprecipitated using anti-tBid (h71) antibody and analyzed for ubiquitin by Western blotting. C, Correlation analysis of tBid O-GlcNAcylation and ubiquitination in bortezomib-treated cells in the presence or absence of ketoconazole and PugNAc (r = −0.7760; left). A schematic diagram showing the interfering effect of O-GlcNAc on tBid ubiquitination (right).

Figure 5.

Drug-like OGA inhibitor ketoconazole (KCZ) increases the O-GlcNAcylation but decreases the ubiquitination of tBid. A, Analysis of O-GlcNAcylation of tBid in response to bortezomib (BTZ) and ketoconazole cotreatment. MCL cells were cotreated with bortezomib (6 nmol/L) and increasing concentrations of KCZ (25–75 μmol/L) or PugNAc (50 μmol/L) for 3 hours. Cell lysates were prepared and immunoprecipitated using control IgG or anti-tBid (h71) antibody and probed with anti-O-GlcNAc antibody. Immunoblots were performed on cell lysates used as IP input using anti-β-actin antibody to confirm equal loading of the samples. B, Analysis of tBid ubiquitination in response to bortezomib and ketoconazole cotreatment. Cells were cotreated with bortezomib (6 nmol/L) and ketoconazole (25–75 μmol/L) or PugNAc (50 μmol/L) in the presence of MG132 (50 μmol/L) for 3 hours. Cell lysates were immunoprecipitated using anti-tBid (h71) antibody and analyzed for ubiquitin by Western blotting. C, Correlation analysis of tBid O-GlcNAcylation and ubiquitination in bortezomib-treated cells in the presence or absence of ketoconazole and PugNAc (r = −0.7760; left). A schematic diagram showing the interfering effect of O-GlcNAc on tBid ubiquitination (right).

Close modal

Ketoconazole enhances bortezomib sensitivity in patient-derived primary cells and de novo bortezomib-resistant MCL cells

To investigate the potential clinical application of bortezomib and ketoconazole combination therapy for MCL, we further tested the sensitizing effect of ketoconazole in acquired bortezomib-resistant MCL cells and in patient-derived primary cells. Drug resistance remains a major clinical challenge for MCL treatment; we thus established de novo bortezomib-resistant cells by continuous exposure of MCL Jeko-1 and Granta-519 cells to increasing concentrations of bortezomib over time. Dose–response curve of the parental and bortezomib-resistant cells was generated and LC25 was calculated from the plot. Bortezomib-resistant Jeko/BTZ500R and Granta/BTZ150R cells exhibited an LC25 approximately 20-fold and 10-fold higher than that of their parental cells, respectively (Supplementary Fig. S7). Treatment of bortezomib-resistant Jeko/BTZ500R and Granta/BTZ150R cells with ketoconazole reduced their LC25 by approximately 50%–65% (Fig. 6A).

Figure 6.

Drug-like OGA inhibitor ketoconazole (KCZ) enhances bortezomib (BTZ) sensitivity in de novo bortezomib-resistant cells and patient-derived primary cells. A, Ketoconazole reduces the LC25 of bortezomib-resistant MCL cells. Bortezomib-resistant Jeko/500R and Granta/150R cells were generated by stepwise selection method (Supplementary Fig. S6) and treated with various concentrations of bortezomib in the presence or absence of ketoconazole (50 μmol/L). Dose–response curves were generated and LC25 of bortezomib in cells treated with bortezomib alone or in combination with ketoconazole were determined and compared. Data are mean ± SD (n = 3). *, P < 0.05 versus LC25 of bortezomib-treated Jeko/BTZ500R or Granta/BTZ150R in the absence of ketoconazole; two-sided Student t test. B, Primary cells were obtained from fresh biopsy-derived lymphoma tissues (lymph nodes; left; scale bar = 1 cm) of MCL patient and were captured for Wright-stained cytospin (right). Clinical characterization of the cells is shown in Supplementary Table S2. C and D, MCL patient-derived primary cells were treated with increasing concentrations of bortezomib (0–6 nmol/L) in the presence or absence of OGA inhibitors, PugNAc (50 μmol/L) and thiamet G (10 μmol/L) (C) or ketoconazole (50–75 μmol/L) (D) for 24 hours and apoptosis was determined by Hoechst 33342 assay. Data are mean ± SD (n = 3). *, P < 0.05 versus bortezomib-treated cells; two-sided Student t test. E, Western blot analysis of activated caspase-3 (cleaved C3) and truncated Bid (tBid) in patient-derived primary cells in response to bortezomib (4 nmol/L) and ketoconazole (50–75 μmol/L) cotreatment. F, A schematic diagram for the regulation of tBid by bortezomib and ketoconazole. In the presence of ketoconazole and other OGA inhibitors, for example, PugNAc and thiamet G, tBid O-GlcNAcylation occurs to inhibit tBid ubiquitination and proteasomal degradation. tBid stabilization intensifies the apoptotic signal and sensitizes MCL to bortezomib-induced apoptosis.

Figure 6.

Drug-like OGA inhibitor ketoconazole (KCZ) enhances bortezomib (BTZ) sensitivity in de novo bortezomib-resistant cells and patient-derived primary cells. A, Ketoconazole reduces the LC25 of bortezomib-resistant MCL cells. Bortezomib-resistant Jeko/500R and Granta/150R cells were generated by stepwise selection method (Supplementary Fig. S6) and treated with various concentrations of bortezomib in the presence or absence of ketoconazole (50 μmol/L). Dose–response curves were generated and LC25 of bortezomib in cells treated with bortezomib alone or in combination with ketoconazole were determined and compared. Data are mean ± SD (n = 3). *, P < 0.05 versus LC25 of bortezomib-treated Jeko/BTZ500R or Granta/BTZ150R in the absence of ketoconazole; two-sided Student t test. B, Primary cells were obtained from fresh biopsy-derived lymphoma tissues (lymph nodes; left; scale bar = 1 cm) of MCL patient and were captured for Wright-stained cytospin (right). Clinical characterization of the cells is shown in Supplementary Table S2. C and D, MCL patient-derived primary cells were treated with increasing concentrations of bortezomib (0–6 nmol/L) in the presence or absence of OGA inhibitors, PugNAc (50 μmol/L) and thiamet G (10 μmol/L) (C) or ketoconazole (50–75 μmol/L) (D) for 24 hours and apoptosis was determined by Hoechst 33342 assay. Data are mean ± SD (n = 3). *, P < 0.05 versus bortezomib-treated cells; two-sided Student t test. E, Western blot analysis of activated caspase-3 (cleaved C3) and truncated Bid (tBid) in patient-derived primary cells in response to bortezomib (4 nmol/L) and ketoconazole (50–75 μmol/L) cotreatment. F, A schematic diagram for the regulation of tBid by bortezomib and ketoconazole. In the presence of ketoconazole and other OGA inhibitors, for example, PugNAc and thiamet G, tBid O-GlcNAcylation occurs to inhibit tBid ubiquitination and proteasomal degradation. tBid stabilization intensifies the apoptotic signal and sensitizes MCL to bortezomib-induced apoptosis.

Close modal

MCL patient-derived primary cells were obtained from fresh patient-derived lymphoma tissues (Fig. 6B; see Supplementary Table S2 for their clinical characterization) and treated with bortezomib in the presence or absence of two well-known small-molecule inhibitors, PugNAc and thiamet-G, or drug-like OGA inhibitor ketoconazole for 24 hours. Figure 6C and D shows that the addition of either small-molecule inhibitor or drug-like inhibitor ketoconazole similarly sensitized the cells to bortezomib-induced apoptosis. Western blot analysis reveals a marked increase in caspase-3 activation in response to the cotreatment of bortezomib and ketoconazole or thiamet G (Fig. 6E). A parallel increase in tBid expression and a reduction in Bid were also observed in the treated cells, thus validating the role of tBid in the apoptosis sensitization in MCL cell lines. Importantly, the combination treatment of bortezomib and ketoconazole had no significant cytotoxic effect on normal PBMCs and hepatocytes at a similar dosing condition (Supplementary Fig. S8). Taken together, our results support the potential clinical application of bortezomib and ketoconazole combination therapy for MCL.

Aberrant hexosamine metabolism and O-GlcNAcylation have been linked to various aggressive behaviors of solid tumors (6, 7), as yet relatively little is known about their roles in hematologic malignancies, particularly MCL. Here, we provide compelling evidence that O-GlcNAcylation of tBid promotes apoptosis of MCL cells in response to its frontline therapeutic agent bortezomib. This finding is in line with a previous report showing reduced doubling time and enhanced cytogenetic abnormalities in CLL cells with a low level of O-GlcNAcylation (RL2 index < 1) relative to those with a higher index (RL2 > 1; ref. 11) and with the survival analyses of DLBCL patients showing better clinical outcomes with low MGEA5 (encoding OGA) expression (Fig. 2D). We further demonstrate that inhibition of OGA and subsequent O-GlcNAcylation by either small-molecule inhibitors or drug-like inhibitor ketoconazole potentiates bortezomib sensitivity in MCL. We highlight for the first time the potential clinical application and molecular mechanism of bortezomib and ketoconazole combination therapy for MCL.

Ketoconazole is a conventional antifungal drug that was recently found to be one of the most potent inhibitors of human and C. perfringen OGAs based on high-throughput screening assays of OGA proteins against a commercial library of 880 off-patent small molecules (20). In this study, we found that ketoconazole, like well-known OGA inhibitors including PugNAc and thiamet G, was able to sensitize MCL cells to bortezomib-induced apoptosis, albeit at approximately 5 times higher molar concentration (Figs. 1 and 2). To our knowledge, this is the first demonstration of the sensitizing effect of OGA inhibitors, specifically ketoconazole, on MCL apoptosis induced by chemotherapeutic agent. Ketoconazole, which sensitizes MCL cells for bortezomib-induced apoptosis, markedly induces Bid cleavage (tBid) with no or minimal effects on other major apoptosis-regulatory proteins (Fig. 3). We herein validate the role of tBid in ketoconazole sensitizing effect and demonstrate that ketoconazole stabilizes tBid, which is generated on stimulation of bortezomib itself and greatly potentiated by ketoconazole cotreatment (Fig. 4). This finding suggests that bortezomib and ketoconazole cooperatively cause tBid accumulation, linking the extrinsic and intrinsic apoptosis pathway and intensifying the death signal.

O-GlcNAcylation is a PTM process that regulates the expression and function of several proteins and has a ubiquitous role in many types of cancer (6, 7). In pancreatic carcinoma MiaPaCa-2 and PANC-1 cells, a decrease in O-GlcNAcylation triggers the intrinsic apoptosis pathway by reducing Bcl-xL, while its upregulation in BxPC-3 cells promotes anoikis resistance in part through NFκB signaling (43). On the other hand, an accumulation of O-GlcNAcylation reduces the viability of breast cancer MCF-7 cells likely through the accumulation of p53 (44). Thus, the role of O-GlcNAcylation in cell death and survival remains unclear and appears to be cell type- and context-dependent. In this study, we found that O-GlcNAcylation of tBid renders MCL cells more susceptible to bortezomib-induced apoptosis. Previous studies have shown that tBid undergoes ubiquitination and subsequently degrades by 26s proteasome (36, 45). The crosstalk between O-GlcNAcylation and ubiquitination are also reported, for example, the counteraction of O-GlcNAcylation and ubiquitination was earlier found to regulate circadian clock proteins, BMAL1 and CLOCK (46), as yet their precise interplay is unclear as enhanced ubiquitination was observed upon increasing of O-GlcNAcylation in the other report (47). Our data indicate that O-GlcNAcylation of tBid interferes with its ubiquitination, as supported by their inverse correlation in all cell systems tested and under various treatment conditions (Fig. 5). Degradation of tBid is known to limit the extent of apoptosis (35, 37), thereby tBid accumulation and stabilization would aid in the amplification and maintenance of apoptosis signal. It is worth noting that the reported sensitizing effect of ketoconazole on bortezomib-induced apoptosis was also seen in patient-derived primary cells and in bortezomib-resistant MCL cells (Fig. 6).

Taken together, the evidence presented here demonstrates the role of tBid O-GlcNAcylation in the regulation of apoptosis in MCL cells. Such PTM improves the stability of tBid by blocking its ubiquitination and subsequent proteasomal degradation, leading to sustained apoptosis, as schematically summarized in Fig. 6F. Our findings not only point to the involvement of hexosamine metabolic pathway and O-GlcNAcylation in MCL response to chemotherapy, but also advise the potential clinical application of drug-like OGA inhibitor ketoconazole in combination therapy to battle against drug-resistant MCL and other malignancies whose development and apoptosis is dependent on tBid dysregulation.

No potential conflicts of interest were disclosed.

Conception and design: S. Luanpitpong, S. Issaragrisil

Development of methodology: S. Luanpitpong

Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc.): S. Luanpitpong, M. Janan, J. Poohadsuan, P. Samart, Y. U.-Pratya, S. Issaragrisil

Analysis and interpretation of data (e.g., statistical analysis, biostatistics, computational analysis): S. Luanpitpong, Y. Rojanasakul

Writing, review, and/or revision of the manuscript: S. Luanpitpong, Y. Rojanasakul, S. Issaragrisil

Administrative, technical, or material support (i.e., reporting or organizing data, constructing databases):

Study supervision: S. Issaragrisil

Other (research assistant): N. Chanthra

S. Issaragrisil is a Senior Research Scholar of Thailand Research Fund. We would like to acknowledge Dr. S. Jirawatnotai from Systems Pharmacology, Department of Pharmacology, Faculty of Medicine Siriraj Hospital, Mahidol University for his technical assistance and Profs. D. Solter and B. Knowles for their comments on the manuscript. This work was supported by grants from Thailand Research Fund (RTA 488-0007, to S. Issaragrisil; TRG5980013, to S. Luanpitpong), the Commission on Higher Education (CHE-RES-RG-49, to S. Issaragrisil), and NIH (R01-ES022968, to Y. Rojanasakul).

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

1.
Hanahan
D
,
Weinberg
RA
. 
Hallmarks of cancer: the next generation
.
Cell
2011
;
144
:
645
74
.
2.
Cheong
H
,
Lu
C
,
Lindsten
T
,
Thompson
CB
. 
Therapeutic targets in cancer cell metabolism and autophagy
.
Nat Biotechnol
2012
;
30
:
671
8
.
3.
Perez-Galan
P
,
Dreyling
M
,
Wiestner
A
. 
Mantle cell lymphoma: biology, pathogenesis, and the molecular basis of treatment in the genomic era
.
Blood
2011
;
117
:
26
38
.
4.
Shah
BD
,
Martin
P
,
Sotomayor
EM
. 
Mantle cell lymphoma: a clinically heterogeneous disease in need of tailored approaches
.
Cancer Control
2012
;
19
:
227
235
.
5.
Bond
MR
,
Hanover
JA
. 
A little sugar goes a long way: the cell biology of O-GlcNAc
.
J Cell Biol
2015
;
208
:
869
80
.
6.
Jóźwiak
P
,
Forma
E
,
Bryś
M
,
Krześlak
A
. 
O-GlcNAcylation and metabolic reprogramming in cancer
.
Front Endocrinol
2014
;
5
:
145
.
7.
de Queiroz
RM
,
Carvalho
E
,
Dias
WB
. 
O-GlcNAcylation: the sweet side of the cancer
.
Front Oncol
2014
;
4
:
132
.
8.
Champattanachai
V
,
Netsirisawan
P
,
Chaiyawat
P
,
Phueaouan
T
,
Charoenwattanasatien
R
,
Chokchaichamnankit
D
, et al
Proteomic analysis and abrogated expression of O-GlcNAcylated proteins associated with primary breast cancer
.
Proteomics
2013
;
13
:
2088
99
.
9.
Lynch
TP
,
Ferrer
CM
,
Jackson
SR
,
Shahriari
KS
,
Vosseller
K
,
Reginato
MJ
. 
Critical role of O-Linked β-N-acetylglucosamine transferase in prostate cancer invasion, angiogenesis, and metastasis
.
J Biol Chem
2012
;
287
:
11070
81
.
10.
Mi
W
,
Gu
Y
,
Han
C
,
Liu
H
,
Fan
Q
,
Zhang
X
, et al
O-GlcNAcylation is a novel regulator of lung and colon cancer malignancy
.
Biochim Biophys Acta
2011
;
1812
:
514
9
.
11.
Shi
Y
,
Tomic
J
,
Wen
F
,
Shaha
S
,
Bahlo
A
,
Harrison
R
, et al
Aberrant O-GlcNAcylation characterizes chronic lymphocytic leukemia
.
Leukemia
2010
;
24
:
1588
98
.
12.
Kouroukis
CT
,
Fernandez
LA
,
Crump
M
,
Gascoyne
RD
,
Chua
NS
,
Buckstein
R
, et al
A phase II study of bortezomib and gemcitabine in relapsed mantle cell lymphoma from the National Cancer Institute of Canada Clinical Trials Group (IND 172)
.
Leuk Lymphoma
2011
;
52
:
394
9
.
13.
Hegde
GV
,
Nordgren
TM
,
Munger
CM
,
Mittal
AK
,
Bierman
PJ
,
Weisenburger
DD
, et al
Novel therapy for therapy-resistant mantle cell lymphoma: multipronged approach with targeting of hedgehog signaling
.
Int J Cancer
2012
;
131
:
2951
60
.
14.
Ma
Z
,
Vosseller
K
. 
Cancer metabolism and elevated O-GlcNAc in oncogenic signaling
.
J Biol Chem
2014
;
289
:
34457
65
.
15.
Chou
TY
,
Hart
GW
,
Dang
CV
. 
c-Myc is glycosylated at threonine 58, a known phosphorylation site and a mutational hot spot in lymphomas
.
J Biol Chem
1995
;
270
:
18961
65
.
16.
Hurtado-Guerrero
R
,
Dorfmueller
HC
,
van Aalten
DM
. 
Molecular mechanisms of O-GlcNAcylation
.
Curr Opin Struct Biol
2008
;
18
:
551
7
.
17.
Yuzwa
SA
,
Macauley
MS
,
Heinonen
JE
,
Shan
X
,
Dennis
RJ
,
He
Y
, et al
A potent mechanism-inspired O-GlcNAcase inhibitor that blocks phosphorylation of tau in vivo
.
Nat Chem Biol
2008
;
4
:
483
90
.
18.
Konrad
RJ
,
Zhang
F
,
Hale
JE
,
Knierman
MD
,
Becker
GW
,
Kudlow
JE
. 
Alloxan is an inhibitor of the enzyme O-linked N-acetylglucosamine transferase
.
Biochem Biophys Res Commun
2002
;
293
:
207
12
.
19.
Dehennaut
V
,
Lefebvre
T
,
Sellier
C
,
Leroy
Y
,
Gross
B
,
Walker
S
, et al
O-linked N-acetylglucosaminyltransferase inhibition prevents G2/M transition in Xenopus laevis oocytes
.
J Biol Chem
2007
;
282
:
12527
36
.
20.
Dorfmueller
HC
,
van Aalten
DMF
. 
Screening-based discovery of drug-like O-GlcNAcase inhibitor scaffolds
.
FEBS Lett
2010
;
584
:
694
700
.
21.
Becattini
B
,
Sareth
S
,
Zhai
D
,
Crowell
KJ
,
Leone
M
,
Reed
JC
, et al
Targeting apoptosis via chemical design: inhibition of bid-induced cell death by small organic molecules
.
Chem Biol
2004
;
11
:
1107
17
.
22.
Amin
HM
,
McDonnell
TJ
,
Medeiros
LJ
,
Rassidakis
GZ
,
Leventaki
V
,
O'Connor
SL
, et al
Characterization of 4 mantle cell lymphoma cell lines
.
Arch Pathol Lab Med
2003
;
127
:
424
31
.
23.
Kridel
R
,
Meissner
B
,
Rogic
S
,
Boyle
M
,
Telenius
A
,
Woolcock
B
, et al
Whole transcriptome sequencing reveals recurrent NOTCH1 mutations in mantle cell lymphoma
.
Blood
2012
;
119
:
1963
71
.
24.
Drexler
HG
. 
Establishment and culture of leukemia-lymphoma cell lines
.
Methods Mol Biol
2011
;
731
:
181
200
.
25.
Zhang
N
,
Fu
JN
,
Chou
TC
. 
Synergistic combination of microtubule targeting anticancer fludelone with cytoprotective panaxytriol derived from panax ginseng against MX-1 cells in vitro: experimental design and data analysis using the combination index method
.
Am J Cancer Res
2016
;
6
:
97
104
.
26.
Qi
LS
,
Larson
MH
,
Gilbert
LA
,
Doudna
JA
,
Weissman
JS
,
Arkin
AP
, et al
Repurposing CRISPR as an RNA-guided platform for sequence-specific control of gene expression
.
Cell
2013
;
152
:
1173
83
.
27.
Larson
MH
,
Gilbert
LA
,
Wang
X
,
Lim
WA
,
Weissman
JS
,
Qi
LS
. 
CRISPR interference (CRISPRi) for sequence-specific control of gene expression
.
Nat Protoc
2013
;
8
:
2180
96
.
28.
Antonov
AV
,
Krestyaninova
M
,
Knight
RA
,
Rodchenkov
I
,
Melino
G
,
Barlev
NA
. 
PPISURV: a novel bioinformatics tool for uncovering the hidden role of specific genes in cancer survival outcome
.
Oncogene
2014
;
33
:
1621
8
.
29.
Luanpitpong
S
,
Li
J
,
Manke
A
,
Brundage
K
,
Ellis
E
,
McLaughlin
SL
, et al
SLUG is required for SOX9 stabilization and functions to promote cancer stem cells and metastasis in human lung carcinoma
.
Oncogene
2016
;
35
:
2824
33
.
30.
Li
H
,
Zhu
H
,
Xu
CJ
,
Yuan
J
. 
Cleavage of BID by caspase 8 mediates the mitochondrial damage in the Fas pathway of apoptosis
.
Cell
1998
;
94
:
491
501
.
31.
Pérez-Galán
P
,
Mora-Jensen
H
,
Weniger
MA
,
Shaffer
AL
 III
,
Rizzatti
EG
,
Chapman
CM
, et al
Bortezomib resistance in mantle cell lymphoma is associated with plasmacytic differentiation
.
Blood
2011
;
117
:
542
52
.
32.
Tait
SWG
,
Green
DR
. 
Mitochondria and cell death: outer membrane permeabilization and beyond
.
Nat Rev Mol Cell Biol
2010
;
11
:
621
32
.
33.
Guicciardi
ME
,
Gores
GJ
. 
Life and death by death receptors
.
FASEB J
2009
;
23
:
1625
37
.
34.
Unterkircher
T
,
Cristofanon
S
,
Vellanki
SH
,
Nonnenmacher
L
,
Karpel-Massler
G
,
Wirtz
CR
, et al
Bortezomib primes glioblastoma, including glioblastoma stem cells, for TRAIL by increasing tBid stability and mitochondrial apoptosis
.
Clin Cancer Res
2011
;
17
:
4019
30
.
35.
Wei
MC
,
Lindsten
T
,
Mootha
VK
,
Weiler
S
,
Gross
A
,
Ashiya
M
, et al
tBID, a membrane-targeted death ligand, oligomerizes BAK to release cytochrome c
.
Genes Dev
2000
;
14
:
2060
71
.
36.
Luo
W
,
Li
J
,
Zhang
D
,
Cai
T
,
Song
L
,
Min
X-M
, et al
Bid mediates anti-apoptotic COX-2 induction through the IKKβ/NFκB pathway due to 5-MCDE exposure
.
Curr Cancer Drug Targets
2010
;
10
:
96
106
.
37.
Breitschopf
K
,
Zeiher
AM
,
Dimmeler
S
. 
Ubiquitin-mediated degradation of the proapoptotic active form of bid. A functional consequence on apoptosis induction
.
J Biol Chem
2000
;
275
:
21648
52
.
38.
Ying
S
,
Seiffert
BM
,
Häcker
G
,
Fischer
SF
. 
Broad degradation of proapoptotic proteins with the conserved Bcl-2 homology domain 3 during infection with Chlamydia trachomatis
.
Infect Immun
2005
;
73
:
1399
1403
.
39.
Mani
A
,
Gelmann
EP
. 
The ubiquitin-proteasome pathway and its role in cancer
.
J Clin Oncol
2005
;
23
:
4776
89
.
40.
Lam
YA
,
Lawson
TG
,
Velayutham
M
,
Zweier
JL
,
Pickart
CM
. 
A proteasomal ATPase subunit recognizes the polyubiquitin degradation signal
.
Nature
2002
;
416
:
763
7
.
41.
Swaney
DL
,
Beltrao
P
,
Starita
L
,
Guo
A
,
Rush
J
,
Fields
S
, et al
Global analysis of phosphorylation and ubiquitylation cross-talk in protein degradation
.
Nat Methods
2013
;
10
:
676
82
.
42.
Hunter
T
. 
The age of crosstalk: phosphorylation, ubiquitination, and beyond
.
Mol Cell
2007
;
28
:
730
8
.
43.
Ma
Z
,
Vocadlo
DJ
,
Vosseller
K
. 
Hyper-O-GlcNAcylation is anti-apoptotic and maintains constitutive NF-κB activity in pancreatic cancer cells
.
J Biol Chem
2013
;
288
:
15121
30
.
44.
Yang
WH
,
Kim
JE
,
Nam
HW
,
Ju
JW
,
Kim
HS
,
Kim
YS
, et al
Modification of p53 with O-linked N-acetylglucosamine regulates p53 activity and stability
.
Nat Cell Biol
2006
;
8
:
1074
83
.
45.
Azakir
BA
,
Desrochers
G
,
Angers
A
. 
The ubiquitin ligase Itch mediates the antiapoptotic activity of epidermal growth factor by promoting the ubiquitylation and degradation of the truncated C-terminal portion of Bid
.
FEBS J
2010
;
277
:
1319
30
.
46.
Li
MD
,
Ruan
HB
,
Hughes
ME
,
Lee
JS
,
Singh
JP
,
Jones
SP
, et al
O-GlcNAc signaling entrains the circadian clock by inhibiting BMAL1/CLOCK ubiquitination
.
Cell Metab
2013
;
17
:
303
10
.
47.
Guinez
C
,
Mir
AM
,
Dehennaut
V
,
Cacan
R
,
Harduin-Lepers
A
,
Michalski
JC
, et al
Protein ubiquitination is modulated by O-GlcNAc glycosylation
.
FASEB J
2008
;
22
:
2901
11
.